Industry: Healthcare

OFF LIST - 761 consecutive market days: OFF LIST as of 05/28/2013 Through 11/14/2016

Resverlogix Corp., a clinical stage biotechnology company, develops small molecule therapeutics for Bromodomain and ExtraTerminal (BET) inhibition. The company is developing apabetalone (RVX-208), a small molecule selective BET domain inhibitor that is in clinical trials for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, Alzheimer s disease, and orphan diseases. Resverlogix Corp. is headquartered in Calgary, Canada.

Current Quote*
Last: $1.113
Change: 0.004
Book: $54.200
Volume: 1,300

As Of: 04/20 12:17 ET
*Quotes delayed by 20min.

Graphs for RVXCF

3 Month Graph

6 Month Graph

1 Year Graph